Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

All appraisals

1,189 appraisals, newest first, page 6 of 12
AppraisalMedicine pageNICE recommendationPublishedStatus
Acalabrutinib for treating chronic lymphocytic leukaemia
NICE TA689
AcalabrutinibOptimised21 Apr 2021Current
Selective internal radiation therapies for treating hepatocellular carcinoma
NICE TA688
—Optimised Not recommended31 Mar 2021
Updated 3 Jul 2024
Current
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
NICE TA687
RibociclibOptimised31 Mar 2021Current
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)
NICE TA686
BlinatumomabTerminated (no company submission)31 Mar 2021Current
Anakinra for treating Still’s disease
NICE TA685
AnakinraOptimised31 Mar 2021Current
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
NICE TA684
NivolumabRecommended17 Mar 2021Current
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
NICE TA683
PembrolizumabOptimised10 Mar 2021Current
Erenumab for preventing migraine
NICE TA682
ErenumabOptimised10 Mar 2021Current
Baricitinib for treating moderate to severe atopic dermatitis
NICE TA681
BaricitinibOptimised3 Mar 2021Current
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
NICE TA680
LenalidomideOptimised3 Mar 2021Current
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
NICE TA679
DapagliflozinOptimised24 Feb 2021Current
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)
NICE TA678
OmalizumabTerminated (no company submission)24 Feb 2021Current
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma
NICE TA677
—Recommended (Cancer Drugs Fund)24 Feb 2021Current
Filgotinib for treating moderate to severe rheumatoid arthritis
NICE TA676
FilgotinibOptimised24 Feb 2021Current
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)
NICE TA675
—Terminated (no company submission)17 Feb 2021Current
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)
NICE TA674
PembrolizumabTerminated (no company submission)17 Feb 2021Current
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
NICE TA673
NiraparibRecommended (Cancer Drugs Fund)17 Feb 2021Current
Brolucizumab for treating wet age-related macular degeneration
NICE TA672
—Optimised3 Feb 2021Current
Mepolizumab for treating severe eosinophilic asthma
NICE TA671
MepolizumabOptimised3 Feb 2021Current
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
NICE TA670
BrigatinibRecommended27 Jan 2021Current
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies
NICE TA669
—Not recommended27 Jan 2021Replaced by TA852
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
NICE TA668
EncorafenibRecommended6 Jan 2021Current
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
NICE TA667
—Recommended16 Dec 2020Current
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
NICE TA666
AtezolizumabOptimised16 Dec 2020Current
Upadacitinib for treating severe rheumatoid arthritis
NICE TA665
UpadacitinibOptimised9 Dec 2020Current
Liraglutide for managing overweight and obesity
NICE TA664
LiraglutideOptimised9 Dec 2020Current
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
NICE TA663
VenetoclaxOptimised Recommended (Cancer Drugs Fund)9 Dec 2020Current
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)
NICE TA662
DurvalumabTerminated (no company submission)25 Nov 2020Current
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
NICE TA661
PembrolizumabOptimised25 Nov 2020Current
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
NICE TA660
DarolutamideRecommended25 Nov 2020Current
Galcanezumab for preventing migraine
NICE TA659
GalcanezumabOptimised18 Nov 2020Current
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
NICE TA658
IsatuximabRecommended (Cancer Drugs Fund)18 Nov 2020Current
Carfilzomib for previously treated multiple myeloma
NICE TA657
CarfilzomibRecommended18 Nov 2020Current
Siponimod for treating secondary progressive multiple sclerosis
NICE TA656
SiponimodRecommended18 Nov 2020Current
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
NICE TA655
NivolumabOptimised21 Oct 2020Current
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
NICE TA654
OsimertinibRecommended14 Oct 2020Current
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
NICE TA653
OsimertinibOptimised14 Oct 2020Current
Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)
NICE TA652
AlpelisibTerminated (no company submission)7 Oct 2020Replaced by TA816
Naldemedine for treating opioid-induced constipation
NICE TA651
NaldemedineRecommended30 Sep 2020Current
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma
NICE TA650
PembrolizumabNot recommended30 Sep 2020Current
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
NICE TA649
Polatuzumab VedotinRecommended23 Sep 2020Current
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)
NICE TA648
DupilumabTerminated (no company submission)9 Sep 2020Current
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)
NICE TA647
EculizumabTerminated (no company submission)2 Sep 2020Current
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)
NICE TA646
—Terminated (no company submission)2 Sep 2020Current
Avelumab with axitinib for untreated advanced renal cell carcinoma
NICE TA645
AvelumabRecommended (Cancer Drugs Fund)2 Sep 2020Replaced by TA1120
Entrectinib for treating NTRK fusion-positive solid tumours
NICE TA644
EntrectinibRecommended (Cancer Drugs Fund)12 Aug 2020Replaced by TA1118
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
NICE TA643
EntrectinibRecommended12 Aug 2020Current
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
NICE TA642
GilteritinibOptimised12 Aug 2020Current
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
NICE TA641
Brentuximab VedotinRecommended12 Aug 2020Current
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
NICE TA640
TreosulfanOptimised5 Aug 2020Current
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
NICE TA639
AtezolizumabRecommended1 Jul 2020Current
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
NICE TA638
AtezolizumabOptimised1 Jul 2020Current
Ranibizumab for treating diabetic retinopathy (terminated appraisal)
NICE TA637
—Terminated (no company submission)30 Jun 2020Current
Eculizumab for treating refractory myasthenia gravis (terminated appraisal)
NICE TA636
EculizumabTerminated (no company submission)30 Jun 2020Current
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)
NICE TA635
RamucirumabTerminated (no company submission)30 Jun 2020Current
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)
NICE TA634
DaratumumabTerminated (no company submission)30 Jun 2020Current
Ustekinumab for treating moderately to severely active ulcerative colitis
NICE TA633
UstekinumabOptimised17 Jun 2020Current
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
NICE TA632
Trastuzumab emtansineRecommended10 Jun 2020Current
Fremanezumab for preventing migraine
NICE TA631
FremanezumabOptimised3 Jun 2020Current
Larotrectinib for treating NTRK fusion-positive solid tumours
NICE TA630
LarotrectinibRecommended (Cancer Drugs Fund)27 May 2020Current
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
NICE TA629
ObinutuzumabRecommended13 May 2020Current
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
NICE TA628
LorlatinibRecommended13 May 2020Current
Lenalidomide with rituximab for previously treated follicular lymphoma
NICE TA627
LenalidomideRecommended7 Apr 2020Current
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
NICE TA626
AvatrombopagRecommended24 Jun 2020Current
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)
NICE TA625
—Terminated (no company submission)4 Mar 2020Current
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
NICE TA624
—Recommended19 Feb 2020Current
Patiromer for treating hyperkalaemia
NICE TA623
PatiromerOptimised13 Feb 2020Current
Sotagliflozin with insulin for treating type 1 diabetes
NICE TA622
SotagliflozinRecommended12 Feb 2020Current
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
NICE TA621
OsimertinibNot recommended22 Jan 2020Current
Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
NICE TA620
OlaparibOptimised Optimised (Cancer Drugs Fund)15 Jan 2020Replaced by TA908
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
NICE TA619
PalbociclibRecommended (Cancer Drugs Fund)15 Jan 2020Replaced by TA836
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)
NICE TA618
AtezolizumabTerminated (no company submission)15 Jan 2020Current
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
NICE TA617
LusutrombopagRecommended8 Jan 2020Current
Cladribine for treating relapsing–remitting multiple sclerosis
NICE TA616
CladribineOptimised19 Dec 2019
Updated 21 May 2024
Current
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
NICE TA615
CannabidiolOptimised18 Dec 2019Current
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
NICE TA614
CannabidiolOptimised18 Dec 2019Current
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy
NICE TA613
—Not recommended20 Nov 2019Replaced by TA953
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
NICE TA612
NeratinibOptimised20 Nov 2019Current
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
NICE TA611
RucaparibRecommended (Cancer Drugs Fund)13 Nov 2019Current
Pentosan polysulfate sodium for treating bladder pain syndrome
NICE TA610
Pentosan Polysulfate SodiumOptimised13 Nov 2019Current
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)
NICE TA609
RamucirumabTerminated (no company submission)30 Oct 2019Current
Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)
NICE TA608
IbrutinibTerminated (no company submission)30 Oct 2019Current
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
NICE TA607
—Recommended17 Oct 2019Current
Lanadelumab for preventing recurrent attacks of hereditary angioedema
NICE TA606
—Optimised16 Oct 2019Current
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
NICE TA605
XeominRecommended9 Oct 2019Current
Idelalisib for treating refractory follicular lymphoma
NICE TA604
IdelalisibNot recommended2 Oct 2019Current
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)
NICE TA603
LenalidomideTerminated (no company submission)25 Sep 2019Current
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE TA602
PomalidomideTerminated (no company submission)25 Sep 2019Current
Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal)
NICE TA601
—Terminated (no company submission)25 Sep 2019Current
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA600
PembrolizumabRecommended (Cancer Drugs Fund)11 Sep 2019Current
Sodium zirconium cyclosilicate for treating hyperkalaemia
NICE TA599
Sodium Zirconium CyclosilicateOptimised4 Sep 2019
Updated 24 Jan 2022
Current
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
NICE TA598
OlaparibRecommended (Cancer Drugs Fund)28 Aug 2019Replaced by TA962
Dapagliflozin with insulin for treating type 1 diabetes
NICE TA597
DapagliflozinOptimised28 Aug 2019Current
Risankizumab for treating moderate to severe plaque psoriasis
NICE TA596
RisankizumabRecommended21 Aug 2019Current
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
NICE TA595
DacomitinibRecommended14 Aug 2019Current
Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)
NICE TA594
Brentuximab VedotinTerminated (no company submission)14 Aug 2019Replaced by TA1059
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
NICE TA593
RibociclibOptimised (Cancer Drugs Fund)14 Aug 2019Replaced by TA687
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
NICE TA592
CemiplimabRecommended (Cancer Drugs Fund)7 Aug 2019Current
Letermovir for preventing cytomegalovirus disease after a stem cell transplant
NICE TA591
LetermovirRecommended31 Jul 2019Current
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
NICE TA590
—Recommended31 Jul 2019Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.